March 9, 2014
Elliott, Perry M
Israel, Carsten W
Vardas, Panos E
Europace. 2013 Aug;15(8):1070-118. doi: 10.1093/europace/eut206. Epub 2013 Jun 24.
Author Address: Department of Cardiology, Ospedali del Tigullio, Via Don Bobbio 25, IT-16033 Lavagna, (GE) Italy.
Reference Type: Journal Article
Record Number: 398Author: Farmakis, D., Parissis, J. and Filippatos, G.
Title: Insights into Onco-Cardiology: atrial fibrillation
Journal: J Am Coll Cardiol
Date: Dec 6
Short Title: Insights into Onco-Cardiology: atrial fibrillation
Alternate Journal: Journal of the American College of Cardiology
ISSN: 1558-3597 (Electronic)
Accession Number: 24361314
Abstract: Atrial fibrillation (AF) has been deemed to occur with an increased frequency in patients with malignancies, particularly in those undergoing cancer surgery. The occurrence of AF in cancer may be related to comorbid states or a direct tumor effect or represent a complication of cancer surgical or medical therapy, while inflammation may be a common denominator for both conditions. Treating AF in patients with malignancies represents a challenge, especially in terms of antithrombotic therapy, since cancer may result to an increased risk of either thrombosis or hemorrhage and an unpredictable anticoagulation response, while thromboembolic risk-prediction scores such as CHADS2may not be applicable. The general lack of evidence imposes an individualized approach to the management of AF in those patients, although some general recommendations based on current guidelines in non-cancer patients and the existing evidence in cancer patients, where available, may be outlined.